The Technical Analyst
Axcella Health Inc [AXLA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Axcella Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.89% $0.401
America/New_York / 29 des 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.182 mill |
| EPS: | -18.25 |
| P/E: | -0.0220 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 2.95 mill |
| Avg Daily Volume: | 0.0545 mill |
| RATING 2023-12-29 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0220 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0220 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.224 - 1.026 ( +/- 155.90%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-01 | Koziel Margaret | Sell | 679 | Common Stock |
| 2023-02-17 | Koziel Margaret | Buy | 70 000 | Stock Option (Right to Buy) |
| 2023-02-17 | Hinshaw William | Buy | 275 000 | Stock Option (Right to Buy) |
| 2023-02-17 | Fehlner Paul | Buy | 70 000 | Stock Option (Right to Buy) |
| 2023-02-10 | Fehlner Paul | Buy | 5 221 | Common Stock |
| INSIDER POWER |
|---|
| 99.86 |
| Last 92 transactions |
| Buy: 44 458 855 | Sell: 477 523 |
Forecast:
01:40 - $1.564
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.401 (-8.89% ) |
| Volume | 0.0068 mill |
| Avg. Vol. | 0.0545 mill |
| % of Avg. Vol | 12.44 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AXLA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AXLA
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Latest Press Releases
2023-09-14 16:30:00 - Press Release
Axcella Announces Reverse Stock Split Effective September 19, 2023
Cambridge, mass.--(business wire)--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (emms), today announced that its board of directors has approved a 1-for-25 reverse stock split of the company's common stock. the reverse stock split will become effective at 5:00 p.m. eastern time on september 18, 2023, after close of trading on the na.
2023-08-29 08:00:00 - Press Release
Axcella Granted Patent For Long Covid Fatigue Treatment
Cambridge, mass.--(business wire)--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (emms), today announced that the u.s. patent and trademark office (uspto) has granted u.s. patent no. 11,737,999 with claims covering methods of use of candidate axa1125, for treating a subject having post-acute sequelae of covid-19 (pasc), a/k/a long co.
2023-08-03 07:30:00 - Press Release
Axcella Reports Second Quarter Financial Results And Provides Business Update
Cambridge, mass.--(business wire)--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (emms), today announced financial results for the second quarter ended june 30, 2023 and provided a business update. “patients are seeking relief from long covid fatigue. axcella's proprietary composition of amino acids in axa1125 in long covid fatigue i.
2023-05-04 16:30:00 - Press Release
Axcella Reports First Quarter Financial Results And Provides Business Update
Cambridge, mass.--(business wire)--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced financial results for the first quarter ended march 31, 2023 and provided a business update. “patients are seeking a long covid therapy, as we have seen represented at the recent bio / solve me and fda patient driven drug development program forums.
2023-04-17 08:00:00 - Press Release
Axcella Announces Two Oral Presentations On Axa1125 For Long Covid Fatigue At Eccmid 2023
Cambridge, mass.--(business wire)--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced two oral presentations of results from the phase 2a clinical trial of axa1125 in the treatment of long covid fatigue at the european congress of clinical microbiology & infectious diseases (eccmid), as a hybrid event both online and in copenhagen, denmark on april 15-18, 2023. lucy e.m. finnigan, ph.d., m.res., b.sc. (hons.), afhea, oxford centre for clinical magnetic resonance research (ocmr), division of cardiovascular medicine, radcliffe department of medicine, university of oxford, will present efficacy results from the axcella-sponsored phase 2a clinical trial...
Latest News
2023-10-08 08:00:48 - InvestorPlace
3 Pharma Stocks to Dump Before the Damage Is Done
Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.
2023-09-20 11:28:22 - InvestorPlace
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.
2023-09-15 11:17:19 - Zacks Investment Research
Are Medical Stocks Lagging Axcella Health (AXLA) This Year?
Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
2023-09-15 09:01:14 - InvestorPlace
Why Is Axcella Health (AXLA) Stock Down 24% Today?
Axcella Health (NASDAQ: AXLA ) stock is taking a beating on Friday after the biotechnology company announced plans for a reverse stock split. According to Axcella Health, shares of AXLA stock are going to undergo a one-for-25 reverse split.
2023-08-31 09:05:59 - InvestorPlace
Why Is Axcella Health (AXLA) Stock Down 21% Today?
Axcella Health (NASDAQ: AXLA ) stock is falling on Thursday following its announcement of a new Covid-19 treatment patent. However, it's not that this is bad news for the clinical-stage biotechnology company.
2023-08-30 10:31:21 - Zacks Investment Research
Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug
Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.
2023-08-29 13:19:01 - InvestorPlace
Why Is Axcella Health (AXLA) Stock Up 280% Today?
A little-known penny stock is among the market's top movers today. Axcella Health (NASDAQ: AXLA ) stock surged by as much as 280% on news that it has been granted an important new patent.
2023-08-29 09:28:55 - Proactive Investors
Axcella Health stock rockets on long Covid patent win
Axcella Health Inc (NASDAQ:AXLA) saw its stock rocket some 240% higher in Tuesday's early deals after the small-cap firm announced it had secured a patent for its treatment for ‘long' Covid fatigue. The company, in a statement, said its treatment candidate AXA1125, based on compositions of ‘endogenous metabolic modulators' (otherwise referred to as EMMs) had been granted a patent from the US Patent and Trademark Office.
2023-08-22 08:04:31 - InvestorPlace
Why Is Axcella Health (AXLA) Stock Up 68% Today?
Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that would act as a catalyst for today's rally.
2023-02-16 07:35:53 - InvestorPlace
Why Is Axcella Health (AXLA) Stock Up 35% Today?
Axcella Health (NASDAQ: AXLA ) stock is on the rise Wednesday as investors react to an update from the FDA. That update has to do with the company's Long Covid Fatigue treatment currently in development.